These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 23937858)

  • 1. Efficacy and safety of pharmacological interventions in second- or later-line treatment of patients with advanced soft tissue sarcoma: a systematic review.
    Sharma S; Takyar S; Manson SC; Powell S; Penel N
    BMC Cancer; 2013 Aug; 13():385. PubMed ID: 23937858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of trabectedin and gemcitabine for advanced soft tissue sarcomas: results of a phase I dose escalating trial of the German Interdisciplinary Sarcoma Group (GISG).
    Kasper B; Reichardt P; Pink D; Sommer M; Mathew M; Rauch G; Hohenberger P
    Mar Drugs; 2015 Jan; 13(1):379-88. PubMed ID: 25591040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: a systematic review and economic evaluation.
    Edwards SJ; Barton S; Thurgar E; Trevor N
    Health Technol Assess; 2015 Jan; 19(7):1-480. PubMed ID: 25626481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protocol for the 2ND-STEP study, Japan Clinical Oncology Group study JCOG1802: a randomized phase II trial of second-line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin and pazopanib.
    Endo M; Kataoka T; Fujiwara T; Tsukushi S; Takahashi M; Kobayashi E; Yamada Y; Tanaka T; Nezu Y; Hiraga H; Wasa J; Nagano A; Nakano K; Nakayama R; Hamada T; Kawano M; Torigoe T; Sakamoto A; Asanuma K; Morii T; Machida R; Sekino Y; Fukuda H; Oda Y; Ozaki T; Tanaka K
    BMC Cancer; 2023 Mar; 23(1):219. PubMed ID: 36890471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Chemotherapy options for patients with advanced soft-tissue sarcoma beyond anthracyclines].
    Italiano A; Toulmonde M; Bui-Nguyen B
    Bull Cancer; 2010 Jun; 97(6):679-86. PubMed ID: 20483708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trabectedin: Ecteinascidin 743, Ecteinascidin-743, ET 743, ET-743, NSC 684766.
    Drugs R D; 2006; 7(5):317-28. PubMed ID: 16922593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic Therapy for Soft Tissue Sarcoma: Proposals for the Optimal Use of Pazopanib, Trabectedin, and Eribulin.
    Kawai A; Yonemori K; Takahashi S; Araki N; Ueda T
    Adv Ther; 2017 Jul; 34(7):1556-1571. PubMed ID: 28547734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of pazopanib in second-line treatment of advanced soft tissue sarcoma in Spain.
    Villa G; Hernández-Pastor LJ; Guix M; Lavernia J; Cuesta M
    Clin Transl Oncol; 2015 Jan; 17(1):24-33. PubMed ID: 24981588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surrogacy of intermediate endpoints for overall survival in randomized controlled trials of first-line treatment for advanced soft tissue sarcoma in the pre- and post-pazopanib era: a meta-analytic evaluation.
    Tanaka K; Kawano M; Iwasaki T; Itonaga I; Tsumura H
    BMC Cancer; 2019 Jan; 19(1):56. PubMed ID: 30634944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mapping the literature: role of trabectedin as a new chemotherapy option in advanced pretreated soft tissue sarcoma.
    Le Cesne A; Domont J; Cioffi A; Bonvalot S; Terrier P; Ray-Coquard I; Alfaro V; Lebedinsky C; Santabarbara P; Blay JY
    Drugs Today (Barc); 2009 Jun; 45(6):403-21. PubMed ID: 19649331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial.
    Gronchi A; Ferrari S; Quagliuolo V; Broto JM; Pousa AL; Grignani G; Basso U; Blay JY; Tendero O; Beveridge RD; Ferraresi V; Lugowska I; Merlo DF; Fontana V; Marchesi E; Donati DM; Palassini E; Palmerini E; De Sanctis R; Morosi C; Stacchiotti S; Bagué S; Coindre JM; Dei Tos AP; Picci P; Bruzzi P; Casali PG
    Lancet Oncol; 2017 Jun; 18(6):812-822. PubMed ID: 28499583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: Subgroup analysis of a phase 3, randomized clinical trial.
    Hensley ML; Patel SR; von Mehren M; Ganjoo K; Jones RL; Staddon A; Rushing D; Milhem M; Monk B; Wang G; McCarthy S; Knoblauch RE; Parekh TV; Maki RG; Demetri GD
    Gynecol Oncol; 2017 Sep; 146(3):531-537. PubMed ID: 28651804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differences in the Efficacies of Pazopanib and Gemcitabine/Docetaxel as Second-Line Treatments for Metastatic Soft Tissue Sarcoma.
    Kim JH; Park HS; Heo SJ; Kim SK; Han JW; Shin KH; Kim SH; Hur H; Kim KS; Choi YD; Kim S; Lee YH; Suh JS; Ahn JB; Chung HC; Noh SH; Rha SY; Kim HS
    Oncology; 2019; 96(2):59-69. PubMed ID: 30336470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trabectedin clinical cases: use according to indication in diverse clinical scenarios.
    Grignani G; Martín-Broto J; Schuler M; Reichardt P
    Future Oncol; 2015; 11(11 Suppl):15-24. PubMed ID: 26043311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How we use pazopanib in treating soft-tissue sarcoma: experience at our multidisciplinary sarcoma centers.
    Van Tine BA; Trent JC
    Curr Med Res Opin; 2019 Apr; 35(4):623-629. PubMed ID: 30652922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomised phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas.
    Blay JY; Leahy MG; Nguyen BB; Patel SR; Hohenberger P; Santoro A; Staddon AP; Penel N; Piperno-Neumann S; Hendifar A; Lardelli P; Nieto A; Alfaro V; Chawla SP
    Eur J Cancer; 2014 Apr; 50(6):1137-47. PubMed ID: 24512981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II of gemcitabine combined with pazopanib followed by pazopanib maintenance, as second-line treatment in patients with advanced leiomyosarcomas: A unicancer French Sarcoma Group study (LMS03 study).
    Pautier P; Penel N; Ray-Coquard I; Italiano A; Bompas E; Delcambre C; Bay JO; Bertucci F; Delaye J; Chevreau C; Cupissol D; Bozec L; Eymard JC; Saada E; Isambert N; Guillemet C; Rios M; Piperno-Neumann S; Chenuc G; Duffaud F
    Eur J Cancer; 2020 Jan; 125():31-37. PubMed ID: 31835236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimizing the use of trabectedin for advanced soft tissue sarcoma in daily clinical practice.
    Le Cesne A; Reichardt P
    Future Oncol; 2015; 11(11 Suppl):3-14. PubMed ID: 26043310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retrospective inter- and intra-patient evaluation of trabectedin after best supportive care for patients with advanced translocation-related sarcoma after failure of standard chemotherapy.
    Araki N; Takahashi S; Sugiura H; Ueda T; Yonemoto T; Takahashi M; Morioka H; Hiraga H; Hiruma T; Kunisada T; Matsumine A; Kawai A
    Eur J Cancer; 2016 Mar; 56():122-130. PubMed ID: 26845175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, open-label, phase 2, multicenter trial of gemcitabine with pazopanib or gemcitabine with docetaxel in patients with advanced soft-tissue sarcoma.
    Somaiah N; Van Tine BA; Wahlquist AE; Milhem MM; Hill EG; Garrett-Mayer E; Armeson KE; Schuetze SM; Meyer CF; Reuben DY; Elias AD; Read WL; Chawla SP; Kraft AS
    Cancer; 2021 Mar; 127(6):894-904. PubMed ID: 33231866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.